Abbott Reports Third-Quarter 2013 Results

                  Abbott Reports Third-Quarter 2013 Results

- Third-Quarter Ongoing EPS of $0.55 (GAAP EPS From Continuing Operations of
$0.49) -

- Announces 57 Percent Increase in Quarterly Common Dividend -

- Confirms Full-Year 2013 Ongoing EPS Guidance Range -

- Delivers Strong Gross Margin and Operating Margin Improvements -

  PR Newswire

  ABBOTT PARK, Illinois, Oct. 16, 2013

ABBOTT PARK, Illinois,Oct. 16, 2013 /PRNewswire/ --Abbott today announced
financial results for the third quarter ended Sept. 30, 2013.

  *Third-quarter adjusted diluted EPS was $0.55, above the previous guidance
    range; reported diluted EPS from continuing operations under GAAP was
    $0.49. Sales growth this quarter was negatively affected by a sales
    disruption in International Nutrition, which was offset in the quarter by
    strong performance across other businesses, gross and operating margin
    improvements, expense controls and a lower tax rate.
  *Abbott is announcing today an increase in the quarterly common dividend of
    57 percent to $0.22 per share, payable on Feb. 15, 2014, to shareholders
    of record at the close of business on Jan. 15, 2014. This will mark the
    42nd consecutive year that Abbott has increased its dividend payout and
    demonstrates Abbott's continued commitment to increasing its return of
    cash to shareholders while investing for long-term growth.
  *Abbott is confirming its full-year 2013 ongoing EPS guidance range of
    $1.98 to $2.04. Including specified items, Abbott's projected full-year
    2013 EPS from continuing operations under GAAP would be $1.46 to $1.52.
  *Excluding foreign exchange, worldwide sales increased 4.3 percent on an
    operational basis. Reported sales increased 2.0 percent, including an
    unfavorable 2.3 percent effect of foreign exchange. The sales disruption
    in International Nutrition is estimated to have reduced Abbott's total
    worldwide sales growth by nearly 2 percentage points.
  *Third-quarter adjusted gross margin ratio of 55.9 percent increased 70
    basis points over prior year, ahead of expectations, driven by continuing
    improvements in Nutrition and Diagnostics. The adjusted operating margin
    ratio of 19.3 percent increased 210 basis points over prior year. The
    gross margin and operating margin ratios under GAAP were 50.7 and 11.7
    percent, respectively.
  *In August, Abbott completed two acquisitions in its Medical Devices
    business: IDEV Technologies, which expands Abbott's endovascular
    portfolio, and OptiMedica, which provides an immediate entry point into
    the laser cataract surgery market.

"We continued to have strong earnings performance, in spite of a supplier
recall that impacted our International Nutrition business," said Miles D.
White, chairman and chief executive officer, Abbott. ''Today we also are
announcing a significant increase in our quarterly dividend."

Third-Quarter Business Overview

Following are the sales by business segment for the third quarter and the
first nine months of the year, as well as commentary addressing third-quarter
sales performance:

Total Company

                                                      % Change vs. 3Q12
                    Sales ($ in
                  millions) 3Q13                    Int'l                  Total
                U.S.   Int'l  Total  U.S.   Operational  Reported  Operational  Reported
Total Sales *   1,587  3,782  5,369    3.3          4.7       1.4          4.3       2.0
Nutrition         725    910  1,635    1.6          4.9       2.2          3.4       1.9
Diagnostics       320    805  1,125   15.0          8.9       5.5         10.5       8.0
Established
Pharmaceuticals     -  1,235  1,235  n/a          0.6     (2.9)          0.6     (2.9)
Medical
Devices           520    822  1,342  (0.1)          6.6       3.2          3.9       1.9
* Total Abbott Sales include Other Sales of $32 million.

                                                        % Change vs. 9M12
                Sales ($ in millions)
                        9M13                          Int'l                  Total
                U.S.   Int'l   Total   U.S.   Operational  Reported  Operational  Reported
Total Sales *   4,681  11,512  16,193  (1.0)          6.1       3.4          4.0       2.1
Nutrition       2,157   2,881   5,038    0.2         12.6      11.1          7.0       6.2
Diagnostics       916   2,433   3,349    7.0          8.6       5.5          8.1       5.9
Established
Pharmaceuticals     -   3,686   3,686  n/a          0.7     (2.4)          0.7     (2.4)
Medical
Devices         1,540   2,486   4,026  (6.4)          4.8       1.7          0.3     (1.5)
* Total Abbott Sales include Other Sales of $94 million.
n/a = Not Applicable.
Note: Operational growth reflects percentage change over the prior year excluding the
impact of exchange rates.

Third-quarter 2013 worldwide sales of $5.4 billion increased 4.3 percent on an
operational basis, with strong performance in Diagnostics and Medical Devices.
The sales disruption in International Nutrition is estimated to have reduced
Abbott's total worldwide sales growth by nearly 2 percentage points. On a
reported basis, sales increased 2.0 percent, including an unfavorable 2.3
percent effect of foreign exchange.

Sales in developed markets in the third quarter were $3.2 billion, increasing
1.8 percent on an operational basis and relatively flat on a reported basis.
This operational sales growth represents a sequential improvement versus
second quarter, driven by low-single-digit growth in Medical Devices and
Nutrition and mid-single-digit growth in Diagnostics. Leading market positions
and new technologies are delivering profitable growth in developed markets. 

Sales in emerging markets in the third quarter were $2.2 billion, increasing
8.1 percent on an operational basis and 5.3 percent on a reported basis.

Nutrition

                                               % Change vs. 3Q12
              Sales ($ in
             millions) 3Q13                  Int'l                  Total
           U.S.  Int'l  Total  U.S.  Operational  Reported  Operational  Reported
Total
Sales       725    910  1,635   1.6          4.9       2.2          3.4       1.9
Pediatric   371    515    886   2.1          3.0       1.7          2.7       1.9
Adult       354    395    749   1.0          7.5       2.9          4.4       2.0

                                                 % Change vs. 9M12
               Sales ($ in
             millions) 9M13                    Int'l                  Total
           U.S.   Int'l  Total  U.S.   Operational  Reported  Operational  Reported
Total
Sales      2,157  2,881  5,038    0.2         12.6      11.1          7.0       6.2
Pediatric  1,127  1,708  2,835    0.4         14.4      14.2          8.4       8.2
Adult      1,030  1,173  2,203  (0.1)         10.2       7.0          5.2       3.6

Worldwide Nutrition sales increased 3.4 percent in the third quarter on an
operational basis and 1.9 percent on a reported basis, including an
unfavorable 1.5 percent effect of foreign exchange. Abbott's broad and diverse
nutritional product portfolio is comprised of approximately 55 percent of
sales in Pediatric Nutrition and 45 percent of sales in Adult Nutrition.

Worldwide Pediatric Nutrition sales increased 2.7 percent on an operational
basis and 1.9 percent on a reported basis in the quarter, including an
unfavorable 0.8 percent effect of foreign exchange. International Pediatric
sales increased 3.0 percent on an operational basis and were negatively
impacted by a supplier recall in early August in certain international markets
of pediatric nutrition products. While there were no health issues associated
with this supplier recall and the supplier subsequently determined that the
products had been safe for consumption, this event created significant
disruption in these markets. As a result, Abbott also anticipates
International Pediatric Nutrition sales in the fourth quarter 2013 and the
first half 2014 to be lower than previous expectations.

The sales disruption is estimated to have reduced sales growth in
International Pediatric Nutrition by approximately $90 million in the third
quarter. Exclusive of this event, International Pediatric Nutrition continues
to drive strong performance as it launches new product innovations and
executes on geographic expansion initiatives.

Worldwide Adult Nutrition sales increased 4.4 percent on an operational basis
and 2.0 percent on a reported basis in the quarter, including an unfavorable
2.4 percent effect of foreign exchange. Sales growth in the quarter was led by
strong growth of Ensure® and continued expansion of the adult nutrition market
where Abbott is the global leader. International Adult Nutrition sales grew
7.5 percent on an operational basis, driven by strong growth in emerging
markets. U.S. Adult Nutrition sales growth was negatively impacted by Abbott's
exit this year from certain non-core business lines as part of the division's
margin improvement initiative, which was offset by double-digit growth of
Ensure.

Diagnostics

                                                % Change vs. 3Q12
               Sales ($ in
              millions) 3Q13                  Int'l                  Total
            U.S.  Int'l  Total  U.S.  Operational  Reported  Operational  Reported
Total
Sales        320    805  1,125  15.0          8.9       5.5         10.5       8.0
Core
Laboratory   187    721    908  15.3          7.7       4.2          9.1       6.3
Molecular     50     67    117   6.7         24.0      22.2         16.0      15.0
Point of
Care          83     17    100  20.1          5.3       2.2         17.1      16.5

                                                % Change vs. 9M12
               Sales ($ in
              millions) 9M13                  Int'l                  Total
            U.S.  Int'l  Total  U.S.  Operational  Reported  Operational  Reported
Total
Sales        916  2,433  3,349   7.0          8.6       5.5          8.1       5.9
Core
Laboratory   521  2,185  2,706   2.1          8.3       5.1          7.1       4.5
Molecular    150    192    342   5.4         14.3      12.3         10.2       9.1
Point of
Care         245     56    301  20.6          1.9       0.8         16.6      16.4

Worldwide Diagnostics sales increased 10.5 percent in the third quarter on an
operational basis. The results exceeded previous expectations and reflect
strong double-digit growth in Molecular and Point of Care Diagnostics, as well
as high single-digit growth in the Core Laboratory business. Reported sales
increased 8.0 percent, including an unfavorable 2.5 percent effect of foreign
exchange. Diagnostics gross and operating margin improved versus the third
quarter of 2012, and this business segment is ahead of schedule to achieve its
operating margin target. Diagnostics is continuing the development of multiple
new system platforms across all of its business units that are designed to
positively impact patient care, improve service to customers, enhance
laboratory productivity, and reduce costs.

Core Laboratory Diagnostics sales increased 9.1 percent in the quarter on an
operational basis, driven by strong growth in key emerging markets and the
United States. Reported sales increased 6.3 percent, including an unfavorable
2.8 percent effect of foreign exchange. International sales growth of 7.7
percent on an operational basis was driven by continued strong performance in
key emerging markets. U.S. growth of 15.3 percent was the result of several
large health system customers selecting Abbott's integrated and flexible
solutions to manage large testing volumes and increase operational
efficiencies. Also in September, preliminary results from a clinical study
sponsored by the British Heart Foundation suggested that Abbott's ARCHITECT
High Sensitive Troponin test, currently available outside the United States,
may help improve the diagnosis and prognosis of patients presenting with
symptoms of a heart attack. Data showed the test could be particularly
beneficial for women, who are often under-diagnosed.

Molecular Diagnostics sales increased 16.0 percent in the quarter on an
operational basis. Reported worldwide Molecular sales increased 15.0 percent,
including an unfavorable 1.0 percent effect of foreign exchange. Sales were
driven by strong infectious disease growth, particularly in emerging markets
due to the impact of recent tenders, as well as the continued growth of
companion diagnostics.

Point of Care Diagnostics also contributed to strong sales growth, increasing
17.1 percent in the quarter on an operational basis and 16.5 percent on a
reported basis, including an unfavorable 0.6 percent effect of foreign
exchange. Abbott holds the leadership position in the United States, where
sales increased 20.1 percent driven by continued growth in the U.S. hospital
segment, as well as strong growth in the physician office segment. Overall
performance was driven by balanced double-digit growth in both developed and
emerging markets, with on-going investments driving further penetration in key
growth markets.

Established Pharmaceuticals

                                              % Change vs. 3Q12
             Sales ($ in
            millions) 3Q13                  Int'l                  Total
          U.S.  Int'l  Total  U.S.  Operational  Reported  Operational  Reported
Total
Sales        -  1,235  1,235   n/a          0.6     (2.9)          0.6     (2.9)
Key
Emerging
Markets      -    573    573   n/a          2.3     (3.4)          2.3     (3.4)
Other
Markets      -    662    662   n/a        (0.9)     (2.4)        (0.9)     (2.4)

                                              % Change vs. 9M12
             Sales ($ in
            millions) 9M13                  Int'l                  Total
          U.S.  Int'l  Total  U.S.  Operational  Reported  Operational  Reported
Total
Sales        -  3,686  3,686   n/a          0.7     (2.4)          0.7     (2.4)
Key
Emerging
Markets      -  1,747  1,747   n/a          5.0       1.1          5.0       1.1
Other
Markets      -  1,939  1,939   n/a        (3.0)     (5.3)        (3.0)     (5.3)
n/a = Not Applicable.

Established Pharmaceuticals sales increased 0.6 percent in the third quarter
on an operational basis and decreased 2.9 percent on a reported basis,
including an unfavorable 3.5 percent effect of foreign exchange.

Sales in Key Emerging Markets increased 2.3 percent on an operational basis in
the quarter. Reported sales decreased 3.4 percent, including an unfavorable
5.7 percent effect of foreign exchange. Abbott is focused on implementing
tailored strategies to drive accelerated growth across its key emerging
markets. While recent macroeconomic and market pressures in certain emerging
markets resulted in somewhat slower sales growth this quarter, growth rates in
emerging markets have and are expected to continue to outpace the overall
global economy and remain attractive over the long-term.

Other Markets include developed markets, such as Western Europe and Japan, and
other emerging markets globally. Sales in these geographies decreased 0.9
percent in the quarter on an operational basis and 2.4 percent on a reported
basis, including an unfavorable 1.5 percent effect of foreign exchange.

Medical Devices

                                                     % Change vs. 3Q12
                   Sales ($ in
                  millions) 3Q13                   Int'l                  Total
                U.S.  Int'l  Total  U.S.   Operational  Reported  Operational  Reported
Total Sales      520    822  1,342  (0.1)          6.6       3.2          3.9       1.9
Vascular         301    446    747    1.8          2.9     (0.2)          2.5       0.6
Diabetes Care    122    197    319  (9.4)          8.7       7.6          1.0       0.4
Medical Optics    97    179    276    7.5         14.0       7.2         11.7       7.3
Vascular
Product Lines:
DES/BVSa)        130    254    384  (6.2)          4.3     (1.2)          0.7     (3.0)
Other Coronary
Productsb)        48     89    137    2.0        (9.3)     (9.9)        (5.7)     (6.1)
Endovascularc)    62     55    117    3.0         10.6      11.6          6.4       6.9

                                                       % Change vs. 9M12
                    Sales ($ in
                  millions) 9M13                     Int'l                   Total
                U.S.   Int'l  Total   U.S.   Operational  Reported   Operational  Reported
Total Sales     1,540  2,486  4,026   (6.4)          4.8       1.7           0.3     (1.5)
Vascular          863  1,377  2,240   (8.7)          3.8       0.7         (1.3)     (3.1)
Diabetes Care     390    570    960   (6.6)          5.4       4.2           0.2     (0.5)
Medical Optics    287    539    826     1.5          7.1       1.9           5.1       1.7
Vascular
Product Lines:
DES/BVSa)         384    776  1,160  (10.2)          5.4       0.6         (0.1)     (3.2)
Other Coronary
Productsb)        145    285    430   (2.0)        (4.0)     (5.2)         (3.3)     (4.2)
Endovascularc)    183    168    351     0.6          7.4       7.6           3.7       3.8
a) ^ Includes drug-eluting stents and bioresorbable
vascular scaffold (BVS) product portfolio.
b) ^ Includes guide wires, balloon catheters and other
coronary products.
c) ^ Includes vessel closure, carotid stents
and other peripheral products.

Worldwide Medical Devices sales increased 3.9 percent in the third quarter on
an operational basis. Reported sales increased 1.9 percent, including an
unfavorable 2.0 percent effect of foreign exchange.

Worldwide Vascular sales increased 2.5 percent in the quarter on an
operational basis, representing a continued sequential improvement versus
second quarter 2013 and consistent with previous guidance. Reported sales
increased 0.6 percent, including an unfavorable 1.9 percent effect of foreign
exchange. International Vascular sales comprise approximately 60 percent of
total Vascular sales and increased 2.9 percent operationally, driven by the
continued share gains in key geographies of XIENCE Xpedition™ and Absorb™,
Abbott's drug eluting coronary bioresorbable vascular scaffold (BVS). In
August, Abbott launched XIENCE Xpedition in Japan, further expanding Abbott's
share position. Growth in sales of MitraClip®, Abbott's first-in-class device
for the treatment of mitral regurgitation, and double-digit sales growth in
Endovascular also contributed to international growth. U.S. Vascular sales
were impacted by a year-over-year market decline, partially offset by an
increase in XIENCE Xpedition market share and growth in Endovascular.

Worldwide Diabetes Care sales increased 1.0 percent in the quarter on an
operational basis. Reported sales increased 0.4 percent, including an
unfavorable 0.6 percent effect of foreign exchange. International sales growth
of 8.7 percent was driven by continued double-digit growth in emerging
markets, partially offset by the expected impact of the implementation of the
CMS competitive bidding program in the United States.

Worldwide Medical Optics sales increased 11.7 percent in the quarter on an
operational basis, exceeding previous expectations. Reported sales increased
7.3 percent, including an unfavorable 4.4 percent effect of foreign exchange.
Cataract sales, which represent approximately 65 percent of total Medical
Optics sales, increased strong double digits, outpacing the market. This
strong growth was driven by share gains of new products, including the recent
launch of the TECNIS® OptiBlue intraocular lens (IOL) in Japan, which provides
Abbott access to the largest segment of the Japan market, and the TECNIS Toric
IOL in the United States for patients with astigmatism, which enables Abbott
to compete in the fastest-growing premium segment of the IOL market. This
growth was partially offset by a decline in refractive sales driven by
continued soft market conditions.

Abbott confirms its full-year 2013 ongoing EPS guidance range

Abbott is confirming its full-year 2013 ongoing earnings-per-share guidance
range of $1.98 to $2.04, reflecting double-digit growth. Abbott forecasts net
specified items for the full year 2013 of approximately $0.52 per share.
Including these net specified items, projected earnings per share from
continuing operations under Generally Accepted Accounting Principles (GAAP)
would be $1.46 to $1.52 for the full year 2013. Specified items are primarily
associated with intangible amortization expense and cost reduction
initiatives, partially offset by favorable adjustments to tax expense related
to the resolution of various tax positions from previous years and the impact
in the first quarter of the favorable effect of U.S. tax law changes enacted
in 2013 related to 2012 results. 

Abbott announces 57 percent dividend increase payable Feb. 2014

Today Abbott is announcing an increase in the company's quarterly common
dividend to $0.22 per share from $0.14 per share, representing an increase of
57 percent. The change takes effect with the dividend that will be paid on
Feb. 15, 2014, to shareholders of record at the close of business on Jan. 15,
2014. This will mark the 42nd consecutive year Abbott has increased its
dividend.

Separately, on Sept. 12, 2013, the board of directors of Abbott declared the
company's quarterly common dividend of $0.14 per share. Abbott's cash dividend
is payable Nov. 15, 2013, to shareholders of record at the close of business
on Oct. 15, 2013.

Abbott is a member of the S&P 500 Dividend Aristocrats Index, which tracks
companies that have annually increased their dividend for 25 consecutive
years.

About Abbott

Abbott (NYSE: ABT) is a global healthcare company devoted to improving life
through the development of products and technologies that span the breadth of
healthcare. With a portfolio of leading, science-based offerings in
diagnostics, medical devices, nutritionals and branded generic
pharmaceuticals, Abbott serves people in more than 150 countries and employs
approximately 70,000 people.

Visit Abbott at www.abbott.com and connect with us on Twitter at @AbbottNews.

Abbott will webcast its live third-quarter earnings conference call through
its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central
time today. An archived edition of the call will be available after 11 a.m.
Central time.

— Private Securities Litigation Reform Act of 1995 — A Caution Concerning
Forward-Looking Statements

Some statements in this news release may be forward-looking statements for
purposes of the Private Securities Litigation Reform Act of 1995. Abbott
cautions that these forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially from those
indicated in the forward-looking statements. Economic, competitive,
governmental, technological and other factors that may affect Abbott's
operations are discussed in Item 1A, "Risk Factors,'' to our Annual Report on
Securities and Exchange Commission Form 10-K/A for the year ended Dec. 31,
2012, and are incorporated by reference. Abbott undertakes no obligation to
release publicly any revisions to forward-looking statements as a result of
subsequent events or developments, except as required by law.

                    Abbott Laboratories and Subsidiaries
                     Consolidated Statement of Earnings
               Third Quarter Ended September 30, 2013 and 2012
                    (in millions, except per share data)
                                 (unaudited)
                                3Q13            3Q12         % Change
Net Sales                        $5,369          $5,265            2.0
Cost of products sold,
excluding amortization
expense                           2,450           2,489          (1.6)
Amortization of
intangible assets                   197             195            0.9
Research and
development                         357             351            1.8
Selling, general, and
administrative                    1,735           1,920          (9.7)
Total Operating Cost
and Expenses                      4,739           4,955          (4.4)
Operating earnings                  630             310          103.3     1)
Net interest expense                 24              88         (73.1)
Net foreign exchange
(gain) loss                           5            (12)            n/m
Other (income) expense,
net                                (27)               3            n/m
Earnings from
Continuing Operations
before taxes                        628             231          171.7     1)
Taxes on Earnings from
Continuing Operations             (145)           (108)         (34.3)     2)
Net Earnings from
Continuing Operations               773             339          128.0     1)
Earnings from
Discontinued
Operations, net of
taxes                               193           1,604            n/m     3)
Net Earnings                       $966          $1,943         (50.3)
Net Earnings from
Continuing Operations
Excluding                         $873            $666           31.1     4)
Specified Items, as
described below
Diluted Earnings per
Common Share from
Continuing Operations             $0.49           $0.21          133.3     1)
Diluted Earnings per Common
Share from Discontinued
Operations                        $0.12           $1.00            n/m
Diluted Earnings per
Common Share                     $0.61           $1.21         (49.6)
Diluted Earnings per
Common Share from
Continuing                       $0.55           $0.42           31.0     4)
Operations, Excluding
Specified Items, as
described below
Average Number of
Common Shares
Outstanding                       1,567           1,589
Plus Dilutive Common
Stock Options and
Awards
     1)      Increase versus prior year primarily relates to strong operating
             performance, certain costs included in Abbott's 2012 Continuing
             Operations that transferred or are being charged to AbbVie in
             2013, as well as lower expense associated with cost reduction
             initiatives in 2013 versus 2012. Net Earnings and EPS also
             reflect a favorable adjustment to tax expense as discussed in
             note 2.
     2)      2013 Taxes on Earnings from Continuing Operations includes a
             favorable adjustment to tax expense of $241 million, or $0.15
             per share, as a result of the resolution of various tax
             positions from previous years. 2012 Taxes on Earnings from
             Continuing Operations includes a favorable adjustment to tax
             expense of $196 million, or $0.12 per share, as a result of the
             resolution of various tax positions from a previous year. These
             favorable items are classified as specified items and are
             excluded from ongoing results, as discussed below.
     3)      2013 Earnings from Discontinued Operations, net of taxes,
             includes a favorable adjustment to tax expense of $193 million,
             or $0.12 per share, as a result of the resolution of various tax
             positions from a previous year related to AbbVie operations.
     4)      2013 Net Earnings from Continuing Operations Excluding Specified
             Items excludes net after-tax charges of $100 million, or $0.06
             per share, for intangible amortization expense; expenses
             associated with cost reduction initiatives; a philanthropic
             contribution to the Abbott Fund; and other costs, including
             integration and separation-related costs; partially offset by a
             favorable tax adjustment, as discussed in note 2.
             2012 Net Earnings from Continuing Operations Excluding Specified
             Items excludes net after-tax charges of $327 million, or $0.21
             per share, as detailed in the 8-K dated April 16, 2013, for
             intangible amortization expense as well as specified items
             previously identified in Abbott's earnings release dated Oct.
             17, 2012, related to Abbott's continuing operations, certain
             costs that transferred or will be charged to AbbVie and, an
             interest expense adjustment to reflect Abbott's capital
             structure after the separation of AbbVie, partially offset by a
             favorable tax adjustment, as discussed in note 2.
NOTES:
             See tables on page 11 for an explanation of certain non-GAAP
 a)         financial information.
b)           "Discontinued Operations" reflect the operations of the AbbVie
             business, which became an independent company onJan.1, 2013.
n/m = Percent change is not meaningful.

                    Abbott Laboratories and Subsidiaries
                     Consolidated Statement of Earnings
                Nine Months Ended September 30, 2013 and 2012
                    (in millions, except per share data)
                                 (unaudited)
                               9M13             9M12          % Change
Net Sales                       $16,193          $15,862            2.1
Cost of products sold,
excluding amortization
expense                           7,427            7,219            2.9
Amortization of
intangible assets                   593              599          (1.0)
Research and
development                       1,066            1,084          (1.7)
Selling, general, and
administrative                    5,234            5,577          (6.1)
Total Operating Cost
and Expenses                     14,320           14,479          (1.1)
Operating earnings                1,873            1,383           35.4    1)
Net interest expense                 73              217         (66.4)
Net foreign exchange
(gain) loss                          44             (23)            n/m
Other (income)
expense, net                       (28)             (35)         (19.8)
Earnings from
Continuing Operations
before taxes                      1,784            1,224           45.7    1)
Taxes on Earnings from
Continuing Operations              (10)              123            n/m    2)
Net Earnings from
Continuing Operations             1,794            1,101           62.9    1)
Earnings from
Discontinued
Operations, net of
taxes                               193            3,809            n/m    3)
Net Earnings                     $1,987           $4,910         (59.5)
Net Earnings from
Continuing Operations
Excluding                       $2,272           $2,000           13.6    4)
Specified Items, as
described below
Diluted Earnings per
Common Share from
Continuing Operations             $1.13            $0.69           63.8    1)
Diluted Earnings per Common
Share from Discontinued
Operations                        $0.12            $2.37            n/m
Diluted Earnings per
Common Share                     $1.25            $3.06         (59.2)
Diluted Earnings per
Common Share from
Continuing                       $1.43            $1.25           14.4    4)
Operations, Excluding
Specified Items, as
described below
Average Number of
Common Shares
Outstanding                       1,576            1,589
Plus Dilutive Common
Stock Options and
Awards
    1)      Increase versus prior year primarily relates to strong operating
            performance, certain costs included in Abbott's 2012 Continuing
            Operations that transferred or are being charged to AbbVie in
            2013, as well as lower expense associated with cost reduction
            initiatives in 2013 versus 2012. Net Earnings and EPS also
            reflect favorable adjustments to tax expense as discussed in note
            2.
    2)      2013 Taxes on Earnings from Continuing Operations includes a
            favorable adjustment to tax expense of $241 million, or $0.15 per
            share, related to the resolution of various tax positions from
            previous years as well as a favorable adjustment to tax expense
            of $103 million, or $0.07 per share, for the impact in the first
            quarter of U.S. tax law changes enacted in 2013 related to 2012
            results. 2012 Taxes on Earnings from Continuing Operations
            includes a favorable adjustment to tax expense of $196 million,
            or $0.12 per share, as a result of the resolution of various tax
            positions from a previous year. These favorable items are
            classified as specified items and are excluded from ongoing
            results, as discussed below.
    3)      2013 Earnings from Discontinued Operations, net of taxes,
            includes a favorable adjustment to tax expense of $193 million,
            or $0.12 per share, as a result of the resolution of various tax
            positions from a previous year related to AbbVie operations.
    4)      2013 Net Earnings from Continuing Operations Excluding Specified
            Items excludes net after-tax charges of $478 million, or $0.30
            per share, for intangible amortization expense; expenses
            associated with cost reduction initiatives; a philanthropic
            contribution to the Abbott Fund; and other costs, including
            integration and separation-related costs; partially offset by
            favorable tax adjustments, as discussed in note 2. 
            2012 Net Earnings from Continuing Operations Excluding Specified
            Items excludes net after-tax charges of $899 million, or $0.56
            per share, as detailed in the 8-K dated April 16, 2013, for
            intangible amortization expense as well as specified items
            previously identified in Abbott's earnings release dated Oct. 17,
            2012, related to Abbott's continuing operations, certain costs
            that transferred or will be charged to AbbVie, and an interest
            expense adjustment to reflect Abbott's capital structure after
            the separation of AbbVie, partially offset by a favorable tax
            adjustment, as discussed in note 2.
NOTES:
            See tables on page 12 for an explanation of certain non-GAAP
c)          financial information.
            "Discontinued Operations" reflect the operations of the AbbVie
d)          business, which became an independent company onJan.1, 2013.
n/m = Percent change is not meaningful.

Non-GAAP Reconciliation of Financial Information
                    Abbott Laboratories and Subsidiaries
              Non-GAAP Reconciliation of Financial Information
               Third Quarter Ended September 30, 2013 and 2012
                    (in millions, except per share data)
                                 (unaudited)
                                                     3Q13
                                        As         Specified     As     % to

                                  Reported (GAAP)    Items    Adjusted  Sales
Intangible Amortization Expense              $197     ($197)        --
Gross Margin                               $2,722       $280    $3,002  55.9%
R&D                                          $357      ($12)      $345   6.4%
SG&A                                       $1,735     ($115)    $1,620  30.2%
Earnings from Continuing
Operations

before taxes                                $628       $407    $1,035
Taxes on Earnings from
Continuing Operations                      ($145)       $307      $162
Net Earnings from Continuing
Operations                                   $773       $100      $873
Diluted Earnings per Share from

Continuing Operations                       $0.49      $0.06     $0.55

Specified items reflect intangible amortization expense of $197 million;
expenses associated with cost reduction initiatives of $99 million; a
philanthropic contribution to the Abbott Fund of $40 million; and other costs
of $71 million, including integration and separation-related costs; partially
offset by a favorable adjustment to tax expense of $241 million related to the
resolution of various tax positions from previous years.

                                                         3Q12
                                         As

                                         reported  Specified     As     % to

                                         (GAAP)      Items    Adjusted  Sales
Intangible Amortization Expense              $195     ($195)        --
Gross Margin                               $2,581       $328    $2,909  55.2%
R&D                                          $351       ($5)      $346   6.6%
SG&A                                       $1,920     ($261)    $1,659  31.5%
Net Interest Expense                          $88      ($62)       $26
Earnings from Continuing Operations
before taxes                                 $231       $656      $887
Taxes on Earnings from Continuing
Operations                                 ($108)       $329      $221
Net Earnings from Continuing Operations      $339       $327      $666
Diluted Earnings per Share from
Continuing Operations                       $0.21      $0.21     $0.42

Specified items, as detailed in the 8-K dated April 16, 2013, include
intangible amortization expense of $195 million as well as $399 million for
specified items related to Abbott's continuing operations, the removal of
certain corporate costs that transferred to AbbVie in the separation and
certain costs that will be charged to AbbVie under transition service
agreements and $62 million for an adjustment to interest expense to reflect
Abbott's capital structure after the separation of AbbVie, partially offset by
a favorable adjustment to tax expense of $196 million related to the
resolution of various tax positions from a previous year, as previously
identified in Abbott's earnings release dated Oct. 17, 2012.

                    Abbott Laboratories and Subsidiaries
              Non-GAAP Reconciliation of Financial Information
                Nine Months Ended September 30, 2013 and 2012
                    (in millions, except per share data)
                                 (unaudited)
                                                        9M13
                                           As

                                        reported  Specified     As     % to

                                         (GAAP)     Items    Adjusted  Sales
Intangible Amortization Expense             $593     ($593)        --
Gross Margin                              $8,173       $823    $8,996  55.6%
R&D                                       $1,066      ($17)    $1,049   6.5%
SG&A                                      $5,234     ($164)    $5,070  31.3%
Net Foreign Exchange (Gain)/Loss             $44      ($15)       $29
Other (Income)/Expense                     ($28)       ($3)     ($31)
Earnings from Continuing Operations
before taxes                             $1,784     $1,022    $2,806
Taxes on Earnings from Continuing
Operations                                 ($10)       $544      $534
Net Earnings from Continuing
Operations                                $1,794       $478    $2,272
Diluted Earnings per Share from
Continuing Operations                      $1.13      $0.30     $1.43

Specified items reflect intangible amortization expense of $593 million;
expenses associated with cost reduction initiatives of $206 million; a
philanthropic contribution to the Abbott Fund of $40 million; and other costs
of $183 million, including integration and separation-related costs; partially
offset by favorable adjustments to tax expense of $241 million related to the
resolution of various tax positions from previous years and $103 million for
the impact in the first quarter of U.S. tax law changes enacted in 2013
related to 2012 results.

                                                         9M12
                                            As

                                         reported  Specified     As     % to

                                          (GAAP)     Items    Adjusted  Sales
Intangible Amortization Expense              $599     ($599)        --
Gross Margin                               $8,044       $784    $8,828  55.7%
R&D                                        $1,084       ($8)    $1,076   6.8%
SG&A                                       $5,577     ($507)    $5,070  32.0%
Net Interest Expense                         $217     ($134)       $83
Earnings from Continuing Operations

before taxes                               $1,224     $1,433    $2,657
Taxes on Earnings from Continuing
Operations                                   $123       $534      $657
Net Earnings from Continuing Operations    $1,101       $899    $2,000
Diluted Earnings per Share from

Continuing Operations                       $0.69      $0.56     $1.25

Specified items, as detailed in the 8-K dated April 16, 2013, include
intangible amortization expense of $599 million as well as $700 million for
specified items related to Abbott's continuing operations, the removal of
certain corporate costs that transferred to AbbVie in the separation and
certain costs that will be charged to AbbVie under transition service
agreements and $134 million for an adjustment to interest expense to reflect
Abbott's capital structure after the separation of AbbVie, partially offset by
a favorable adjustment to tax expense of $196 million related to the
resolution of various tax positions from a previous year, as previously
identified in Abbott's earnings release dated Oct. 17, 2012.

Tax Rate Reconciliation

Abbott's year-to-date Tax Rate on Earnings from Continuing Operations is 19.0
percent on ongoing basis and (0.6%) on a GAAP basis. A reconciliation of the
year-to-date tax rates for 2013 and 2012 is shown below:

                                               9M13
(dollars in                  Pre-Tax         Taxes on
millions)                   Income 1)        Earnings        Tax Rate
As reported (GAAP)                1,784            (10)          (0.6%)
Specified Items                   1,022             544           53.2%    2)
Excluding specified
items                             2,806             534           19.0%
                                               9M12
(dollars in                  Pre-Tax         Taxes on
millions)                   Income 1)        Earnings        Tax Rate
As reported (GAAP)                1,224             123           10.1%
Specified Items                   1,433             534           37.3%    3)
Excluding specified
items                             2,657             657           24.7%
      1) Pre-Tax Income from Continuing Operations.
         Specified Items include a favorable adjustment to tax expense of
         $241 million from the resolution of various tax positions from
         previous years as well as a favorable adjustment to tax expense of
         $103 million for the impact in the first quarter of U.S. tax law
      2) changes enacted in 2013 related to 2012 results.
         Specified Items include a favorable adjustment to tax expenseof
      3) $196 million from the resolution of a previous year's tax positions.

A reconciliation of the third-quarter tax rates for 2013 and 2012 is shown
below:

                                                3Q13
                               Pre-Tax         Taxes on
(dollars in millions)         Income 4)        Earnings        Tax Rate
As reported (GAAP)                    628           (145)        (23.0%)
Specified Items                       407             307          75.5%   5)
Excluding specified
items                               1,035             162          15.7%
                                                3Q12
                               Pre-Tax         Taxes on
(dollars in millions)         Income 4)        Earnings        Tax Rate
As reported (GAAP)                    231           (108)        (46.5%)
Specified Items                       656             329          50.2%   6)
Excluding specified
items                                 887             221          25.0%
         4) Pre-Tax Income from Continuing Operations.
            Specified Items include a favorable adjustment to tax expense of
            $241 million from the resolution of various tax positions from
         5) previous years.
            Specified Items include a favorable adjustment to tax expense of
            $196 million from the resolution of a previous year's tax
         6) positions.

Website: http://www.abbott.com
Contact: Financial: Brian Yoor, +1-847-937-6343; or Tina Ventura,
+1-847-935-9390; or Scott Leinenweber, +1-847-935-1898; or Media: Scott
Stoffel, +1-847-936-9502; or Angela Duff, +1 (847) 938-6894
 
Press spacebar to pause and continue. Press esc to stop.